Literature DB >> 18341416

Diagnosis of ovarian cancer by Raman spectroscopy: a pilot study.

K Maheedhar1, Rani A Bhat, R Malini, N B Prathima, Patil Keerthi, Pralhad Kushtagi, C Murali Krishna.   

Abstract

OBJECTIVE: To assess the efficacy of conventional Raman spectroscopy in combination with discriminating parameters, Mahalanobis distance, spectral residuals, and "limit test" methodology in differentiation of normal and malignant ovarian tissues. BACKGROUND DATA: Ovarian cancer is the second most common cancer among women and the leading cause of death among gynecologic malignancies. Initial laparotomy and subsequent frozen section analysis can influence the surgical management of ovarian cancers. Although frozen section pathology is sensitive and specific enough, interpretation is often subjective, time consuming, and requires highly skilled personnel. Raman spectroscopy is sensitive to biochemical variations in the samples, rapid, more objective, and amenable to multivariate statistical tools. It can therefore be an ideal tool for discrimination between normal and malignant ovarian tissues.
METHODS: 72 Spectra from eight normal and seven malignant ovarian tissues were recorded by conventional near-infrared (NIR) Raman spectroscopy (excitation wavelength of 785 nm). Spectral data were analyzed by principal components analysis (PCA) and other discriminating parameters such as Mahalanobis distance, spectral residuals, and a multiparametric limit test approach.
RESULTS: A mean malignant spectrum exhibits a broader amide I band, a stronger amide III band, a minor blue shift in the delta CH2 band, and a hump around 1480 cm(-1) compared to a normal spectrum. The normal spectra show relatively stronger peaks around the 855 and 940 cm(-1) region. Scores of factor 1 as well as Mahalanobis distance and spectral residuals gave good classification among the tissue types. The limit test approach provided unambiguous and objective discrimination.
CONCLUSION: The findings of this study demonstrate the efficacy of conventional Raman spectroscopy and our statistical methodologies in discrimination of normal from malignant ovarian tissues. Prospectively, by evaluating the models and developing suitable fiberoptic probes, this technique could be useful in diagnosis during initial laparotomy.

Entities:  

Mesh:

Year:  2008        PMID: 18341416     DOI: 10.1089/pho.2007.2128

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  5 in total

1.  Preclinical evaluation of Raman nanoparticle biodistribution for their potential use in clinical endoscopy imaging.

Authors:  Cristina L Zavaleta; Keith B Hartman; Zheng Miao; Michelle L James; Paul Kempen; Avnesh S Thakor; Carsten H Nielsen; Robert Sinclair; Zhen Cheng; Sanjiv S Gambhir
Journal:  Small       Date:  2011-05-24       Impact factor: 13.281

2.  Clinical research device for ovarian cancer detection by optical spectroscopy in the ultraviolet C-visible.

Authors:  Ronie George; Archana Chandrasekaran; Molly A Brewer; Kenneth D Hatch; Urs Utzinger
Journal:  J Biomed Opt       Date:  2010 Sep-Oct       Impact factor: 3.170

3.  Raman spectroscopic methods for classification of normal and malignant hypopharyngeal tissues: an exploratory study.

Authors:  Parul Pujary; K Maheedhar; C Murali Krishna; Kailesh Pujary
Journal:  Patholog Res Int       Date:  2011-07-24

4.  Identification of Lesional Tissues and Nonlesional Tissues in Early Gastric Cancer Endoscopic Submucosal Dissection Specimens Using a Fiber Optic Raman System.

Authors:  Zhaohui Luan; Yusi Qin; Jianhua Dai; Hongbo Wu; Yao Chen; Xiaofeng Feng; Guiyong Peng
Journal:  Gastroenterol Res Pract       Date:  2020-05-15       Impact factor: 2.260

5.  A comparative analysis of different biofluids towards ovarian cancer diagnosis using Raman microspectroscopy.

Authors:  Panagiotis Giamougiannis; Camilo L M Morais; Rita Grabowska; Katherine M Ashton; Nicholas J Wood; Pierre L Martin-Hirsch; Francis L Martin
Journal:  Anal Bioanal Chem       Date:  2020-11-26       Impact factor: 4.142

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.